$5.51 -0.09 (-1.61%)
12/3/2009 4:00 PM

Maxygen, Inc. (MAXY)

CAPS Rating: 2 out of 5

A biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions.

Recs

2
Member Avatar zzlangerhans (99.57) Submitted: 11/10/2008 11:01:04 AM : Underperform Start Price: $4.69 MAXY Score: +5.82

Despite having a decent cash position the company has decided to defer further development of Maxy-G34 until a partner is found to fund it. Given that this is their only program in clinical development, it's difficult to see where things go from here. I know that Neose's GCSF analogue didn't attract a partner and that stock is trading in pennies.

Report this Post 0 Comments

Featured Broker Partners